European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177309 - 177309
Published: Jan. 1, 2025
Language: Английский
Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2478 - 2478
Published: July 7, 2024
The rise of drug resistance in cancer cells presents a formidable challenge modern oncology, necessitating the exploration innovative therapeutic strategies. This review investigates latest advancements overcoming mechanisms employed by cells, focusing on emerging modalities. intricate molecular insights into resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, promising avenues offered targeted therapies, combination treatments, immunotherapies, precision medicine approaches highlighted. Specifically, synergistic effects combining traditional cytotoxic agents with molecularly inhibitors to circumvent pathways examined. Additionally, evolving landscape immunotherapeutic interventions, immune checkpoint adoptive cell is explored terms bolstering anti-tumor responses evasion mechanisms. Moreover, significance biomarker-driven strategies for predicting monitoring treatment underscored, thereby optimizing outcomes. For future direction paradigms, current focused prevailing challenges improving patient outcomes, through an integrative analysis these
Language: Английский
Citations
34
EClinicalMedicine, Journal Year: 2024, Volume and Issue: 73, P. 102684 - 102684
Published: June 20, 2024
The FDA's alerts regarding the T-cell lymphoma risk post CAR-T therapy has garnered global attention, yet a comprehensive profile of second primary malignancies (SPMs) following treatment is lacking.
Language: Английский
Citations
17
Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)
Published: Jan. 13, 2025
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.
Language: Английский
Citations
16
Experimental Hematology and Oncology, Journal Year: 2023, Volume and Issue: 12(1)
Published: Sept. 22, 2023
Prostate cancer (PC) is one of the most common cancers in males and fifth leading reason death. Age, ethnicity, family history, genetic defects are major factors that determine aggressiveness lethality PC. The African population at highest risk developing high-grade It can be challenging to distinguish between low-risk high-risk patients due slow progression Prostate-specific antigen (PSA) a revolutionary discovery for identification However, it has led an increase over diagnosis treatment PC past few decades. Even if modifications made standard PSA testing, specificity not been found significant. Our understanding genetics proteomics improved advances different fields. New serum, urine, tissue biomarkers, such as 3 (PCA3), have various new diagnostic tests, prostate health index, 4K score, PCA3. These tests significantly reduce number unnecessary repeat biopsies performed. Chemotherapy, radiotherapy, prostatectomy options. newer novel hormone therapy drugs with better response identified. Androgen deprivation hormonal evolving options managing hormone-sensitive castration-resistant This review aimed highlight discuss epidemiology, factors, developments regimens.
Language: Английский
Citations
27
EBioMedicine, Journal Year: 2024, Volume and Issue: 106, P. 105266 - 105266
Published: Aug. 1, 2024
The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR products, alternative strategies to produce cells directly body have been developed recent years. These involve direct infusion of genes via engineered nanocarriers or viral vectors generate situ. This review offers comprehensive overview advancements development cell-targeted generation Additionally, it identifies challenges method potential these issues.
Language: Английский
Citations
15
Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)
Published: Aug. 5, 2024
Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.
Language: Английский
Citations
12
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9463 - 9463
Published: Aug. 30, 2024
Colorectal cancer (CRC) represents a significant global health burden, with high incidence and mortality rates worldwide. Recent progress in research highlights the distinct clinical molecular characteristics of colon versus rectal cancers, underscoring tumor location's importance treatment approaches. This article provides comprehensive review our current understanding CRC epidemiology, risk factors, pathogenesis, management strategies. We also present intricate cellular architecture colonic crypts their roles intestinal homeostasis. carcinogenesis multistep processes are described, covering conventional adenoma-carcinoma sequence, alternative serrated pathways, influential Vogelstein model, which proposes sequential
Language: Английский
Citations
9
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6537 - 6537
Published: Oct. 30, 2024
Next-generation immunotherapies have revolutionized cancer treatment, offering hope for patients with hard-to-treat tumors. This review focuses on the clinical applications and advancements of key immune-based therapies, including immune checkpoint inhibitors, CAR-T cell therapy, new vaccines designed to harness system combat malignancies. A prime example is success pembrolizumab in treatment advanced melanoma, underscoring transformative impact these therapies. Combination treatments, integrating immunotherapy chemotherapy, radiation, targeted are demonstrating synergistic benefits improving patient outcomes. also explores evolving role personalized immunotherapy, guided by biomarkers, genomic data, tumor environment, better target individual Although significant progress has been made, challenges such as resistance, side effects, high costs persist. Technological innovations, nanotechnology artificial intelligence, explored future enablers The evaluates trials, breakthroughs, emerging immune-modulating agents delivery systems that hold great promise enhancing efficacy, reducing toxicity, expanding access immunotherapy. In conclusion, this highlights ongoing reshaping care, strategies poised overcome current further extend therapeutic reach.
Language: Английский
Citations
9
Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: Feb. 10, 2025
Abstract Background Epstein-Barr virus (EBV) is an oncovirus belonging to the herpesvirus family, associated with pathogenesis of multiple malignancies, particularly Burkitt lymphoma (BL). The remains latent in host cells and plays a critical role tumor progression through various mechanisms. A key glycoprotein, gp350, expressed during lytic phase EBV, instrumental viral entry into B presents unique antigenic target, making it promising candidate for immunotherapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) therapy. Methods In this study, we engineered CAR-T targeted against gp350 glycoprotein assessed their therapeutic potential series vitro vivo experiments. efficacy gp350-CAR-T was evaluated by comparing cytotoxic effects both EBV-positive -negative cell lines. We utilized xenograft model monitor impact administration on overall survival. Results demonstrated potent cytotoxicity specifically our model, resulted significant inhibition growth, highlighting capability effectively target eliminate lymphomas. This selectivity underscores utilizing specific immunotherapy. Conclusion Our findings advocate clinical application gp350-directed therapy prospective treatment strategy patients relapsed or refractory tumors. Given encouraging preclinical results, further research warranted optimize production processes extend other EBV-associated paving way improved outcomes affected patient populations.
Language: Английский
Citations
1
World Journal of Transplantation, Journal Year: 2025, Volume and Issue: 15(2)
Published: Feb. 21, 2025
Despite existing curative options like surgical removal, tissue destruction techniques, and liver transplantation for early-stage hepatocellular carcinoma (HCC), the rising incidence mortality rates of this global health burden necessitate continuous exploration novel therapeutic strategies. This review critically assesses dynamic treatment panorama HCC, focusing specifically on burgeoning role immunotherapy in two key contexts: HCC downstaging advanced to facilitate transplant candidacy. It delves into unique immunobiology highlighting tumor-mediated immune evasion mechanisms. Analyzing diverse immunotherapeutic approaches including checkpoint inhibitors, cytokine modulators, vaccines, oncolytic viruses, antigen-targeting antibodies, adoptive cell therapy, acknowledges limitations current diagnostic markers alpha-fetoprotein glypican-3 emphasizes need biomarkers patient selection monitoring. Exploring rationale neoadjuvant adjuvant research is actively exploring safety effectiveness through ongoing clinical trials. The further explores potential benefits challenges combining transplant, careful selection, meticulous monitoring, strategies mitigate post-transplant complications. Finally, latest findings from landscape future directions management, paving way optimizing improving long-term survival patients with challenging malignancy.
Language: Английский
Citations
1